


Systemic Lupus Erythematosus Test

Biohit has developed a unique method for diagnosing systemic lupus erythematosus (SLE). The Biohit Anti-dsDNA IgG ELISA test measures, by a sensitive and specific enzyme immunoassay procedure, telomere antibodies in the serum of a SLE patient.



Biohit Systemic Lupus Erythematosus Test is based on the use of the double-stranded telomeric DNA as the capture antigen for the binding of SLE antibodies.

Telomeres, which represent 0.15 % of the human genome, are highly repetitive sequences of the DNA (TTAGGG/CCCTAA)_n at the end of eukaryotic chromosomes. Human antibodies against telomeric DNA have proven to be a specific and sensitive test for SLE.

As SLE resembles autoimmune rheumatic diseases the Biohit SLE test can be used in the differential diagnosis of SLE and e.g., rheumatoid arthritis, as well as in the assessment of the clinical activity of SLE.

Clinical Background

Systemic lupus erythematosus (SLE) is a typical autoimmune disease, which affects almost every organ of the body and which, with its various symptoms, resembles rheumatic diseases. Although SLE mainly affects women, also men and even children can be affected. Common disorders related to SLE are malar rash, discoid rash, sensitivity to sunlight, oral ulcers, arthritis, serositis, kidney problems (e.g. proteinuria), problems related with the central nervous system, blood circulation, the immune system, as well as antinuclear antibodies. Approximately 2% of the global population suffer from rheumatic diseases and 0.1 - 0.4% from SLE.

On the basis of the titers of telomere antibodies it is possible to distinguish SLE, e.g., from rheumatoid arthritis. The observation that telomerase activity is detected in 85% of all cancers has made the telomerase enzyme a new cancer marker and added special interest on telomere research itself.



Ordering information

Cat. No.	Product	Quantity
604 010	Anti-dsDNA IgG ELISA Kit	96 tests

For research use only. Not for use in diagnostic procedures.

Benefits

- High affinity to anti-dsDNA
- Increased specificity (human DNA sequence as a capture antigen)
 - Reduced background, no cross-reactions
- High reproducibility
- Easily automated



Headquarters Biohit Oyj

Laippatie 1 • 00880 Helsinki • Finland • Tel. +358 9 773 861 • Fax +358 9 773 86 200

info@biohit.com • www.biohit.com